Synthesis and biological evaluation of 1-methyl-2-(3′,4′, 5′-trimethoxybenzoyl)-3-aminoindoles as a new class of antimitotic agents and tubulin inhibitors

Journal of Medicinal Chemistry

Volumn 51, Issue 5, 2008, Pages 1464-1468

  Romagnoli, Romeo ^a   Baraldi, Pier Giovanni ^a   Sarkar, Taradas ^f   Carrion, Maria Dora ^a   Cara, Carlota Lopez ^a   Cruz Lopez, Olga ^a   Preti, Delia ^a   Tabrizi, Mojgan Aghazadeh ^a   Tolomeo, Manlio ^b   Grimaudo, Stefania ^b   Di Cristina, Antonella ^b   Zonta, Nicola ^d   Balzarini, Jan ^c   Brancale, Andrea ^d   Hsieh, Hsing Pang ^e   Hamel, Ernest ^f  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 2 (3,4,5 TRIMETHOXYBENZOYL) 3 AMINO 7 METHOXYINDOLE DERIVATIVE; ANTIMITOTIC AGENT; INDOLE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING SITE; CELL DEATH; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN;

ANIMALS; ANTIMITOTIC AGENTS; BINDING SITES; BIOPOLYMERS; CELL LINE, TUMOR; COLCHICINE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; MICE; MODELS, MOLECULAR; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS;

EID: 41649113513     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7011547     Document Type: Article

References (21)

1. Mahindroo, N.; Liou, J. P.; Chang, J. Y.; Hsieh, H. P. Antitubulin agents for the treatment of cancer - a medicinal chemistry update. Expert. Opin. Ther. Pat. 2006, 16, 647-691.
2. (a) Chaplin, D. J.; Horsman, M. R.; Siemann, D. W. Current development status of small molecules vascular disrupting agents. Curr. Opin. Invest. Drugs 2006, 7, 522-528.
3. (b) Lippert, J. W., III. Vascular disrupting agents. Bioorg. Med. Chem. 2007, 15, 605-615.
4. (c) Siemann, D. W. Vascular-Targeted Therapies in Oncology; John Wiley and Sons: New York, 2006.
5. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989, 45, 209-211.
6. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989, 28, 6984-6991.
7. Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal chemistry of combretastatin A4: present and future directions. J. Med. Chem. 2006, 49, 3033-3044.
8. Pettit, G. R.; Toki, B.; Herald, D. L.; Verdier-Pinard, P.; Boyd, M. R.; Hamel, E.; Pettit, R. K. Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J. Med. Chem. 1998, 41, 1688-1695.
9. Liou, J. P.; Chang, C. W.; Song, J. W.; Yang, Y. N.; Yeh, C. F.; Tseng, H. Y.; Lo, Y. K.; Chang, Y. L.; Chang, C. M.; Hsieh, H. P. Synthesis and struture-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. J. Med. Chem. 2002, 45, 2556-2572.
10. Romagnoli, R.; Baraldi, P. G.; Carrion, M. D.; Lopez Cara, C.; Preti, D.; Fruttarolo, F.; Pavani, M. G.; Tabrizi, M. A.; Tolomeo, M.; Grimaudo, S.; Di Antonella, C.; Balzarini, J.; Hadfield, J. A.; Brancale, A.; Hamel, E. Synthesis and biological evaluation of 2- and 3-aminobenzo[b]thiophene derivatives as antimitotic agents and inhibitors of tubulin polymerization. J. Med. Chem. 2007, 50, 2273-2277.
11. Lima, L. M.; Barreiro, E. J. Bioisosterism: a useful strategy for molecular modification and drug design. Curr. Med. Chem. 2005, 12 (1), 23-49.
12. Brancale, A.; Silvestri, R. Indole, a core nucleus for potent inhibitors of tubulin polymerization. Med. Res. Rev. 2006, 27, 209-238, and references therein.
13. (a) Liou, J. P.; Wu, C.-Y.; Hsieh, H.-P.; Chang, C.-Y.; Chen, C.-M.; Kuo, C.-C.; Chang, J.-Y. 4- and 5-Aroylindoles as novel classes of potent antitubulin agents. J. Med. Chem. 2007, 50, 4548-4552.
14. (b) Hu, L.; Jiang, J.-D.; Qu, J.; Li, Y.; Jin, J.; Li, Z.-R.; Boykin, D. W. Novel potent antimitotic heterocylic ketones: synthesis, antiproliferative activity, and structure-activity relationships. Bioorg. Med. Chem. Lett. 2007, 17, 3613-3617.
15. (c) La Regina, G.; Edler, M. C.; Brancale, A.; Kandil, S.; Clouccia, A.; Piscitelli, F.; Hamel, E.; De Martino, G.; Matesanz, R.; Diaz, J. F.; Scovassi, A. I.; Prosperi, E.; Lavecchia, A.; Novellino, E.; Artico, M.; Silvestri, R. Arylthioindole inhibitors of tubulin polymerization. 3. Biological evaluation, structure-activity relationships and molecular modeling studies. J. Med. Chem. 2007, 50, 922-931.
16. (a) For 2-aroylindole derivatives, see the following: Mahboobi, S.; Pongratz, H.; Hufsky, H.; Hockemeyer, J.; Frieser, M.; Lyssenko, A.; Paper, D. H.; Burgermeister, J.; Bohmer, F. D.; Fiebig, H. H.; Burger, A. M.; Baasner, S.; Beckers, T. Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. J. Med. Chem. 2001, 44, 4535-4553.
17. (b) For 3-aroylindole derivatives see the following: Liou, J. P.; Chang, Y. L.; Kuo, F. M.; Chang, C. W.; Tseng, H. Y.; Wang, C. C.; Yang, Y. N.; Chang, J. Y.; Lee, S. J.; Hsieh, H. P. Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin Agents. J. Med. Chem. 2004, 47, 4247-4257.
18. Hamel, E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin. Cell Biochem. Biophys. 2003, 38, 1-21.
19. Verdier-Pinard, P.; Lai, J.-Y.; Yoo, H.-D.; Yu, J.; Marquez, B.; Nagle, D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol. Pharmacol. 1998, 53, 62-67.
20. Molecular Operating Environment (MOE 2008); Chemical Computing Group, Inc.: Montreal, Quebec, Canada, 2008; http://www.chemcomp.com.
21. Ravelli, R. B. G.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004, 428, 198-202.